Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 1/20 | 0.43 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.39 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.38 |
| ▸ | IDO1 | P14902 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | PLAAT3 | P53816 | 1/20 | 0.37 |
| ▸ | PLAAT5 | Q96KN8 | 1/20 | 0.37 |
| ▸ | PLAAT2 | Q9NWW9 | 1/20 | 0.37 |
| ▸ | PLAAT4 | Q9UL19 | 1/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3732183 | 0.83 | KIF11 (0.60) | KIF11NR3C2MAOBALDH1A1TAAR1 | |
| SCHEMBL3743690 | 0.83 | KIF11 (0.60) | KIF11NR3C2MAOBALDH1A1TAAR1 | |
| SCHEMBL3734918 | 0.80 | KIF11 (0.40) | KIF11NR3C2MAOBTAAR1PLAAT3 | |
| SCHEMBL6634752 | 0.79 | KMT2A (0.57) | KIF11MRGPRX4KMT2A | |
| SCHEMBL3736072 | 0.79 | KIF11 (0.42) | KIF11MAOBMRGPRX4KMT2APLAAT3 | |
| SCHEMBL3729914 | 0.78 | MAOB (0.55) | NR3C2MAOBTAAR1HDAC1HDAC8 | |
| SCHEMBL3739838 | 0.78 | KIF11 (0.49) | KIF11NR3C2MAOBTAAR1MRGPRX4 | |
| SCHEMBL3743140 | 0.77 | MMP1 (0.48) | ALDH1A1KMT2A | |
| SCHEMBL2760705 | 0.77 | NNMT (0.36) | ALDH1A1POLBL3MBTL1KMT2A | |
| SCHEMBL14480241 | 0.75 | NNMT (0.37) | ALDH1A1POLBL3MBTL1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2114867-B1 | AMINOAMIDES AS OREXIN ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2012-12-12 | — | — | EP | disclosed |
| US-7829563-B2 | Aminoamides as orexin antagonists | HOFFMANN-LA ROCHE INC. (US) | 2010-11-09 | — | — | US | disclosed |
| US-20080221166-A1 | AMINOAMIDES AS OREXIN ANTAGONISTS | HOFFMANN-LA ROCHE, INC. | 2008-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221166-A1 | AMINOAMIDES AS OREXIN ANTAGONISTS | HCRTR1, HCRTR2, HRH3 | KIF11 4556/4885NR3C2 325/4885MAOB 716/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.